Treatment of short bowel syndrome patients with colon-in-continuity
View Patent ↗Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
1. A method for enhancing intestinal absorption in a patient with short bowel syndrome presenting with colon in continuity with remnant small intestine, comprising the steps of selecting for treatment a short bowel syndrome patient presenting with colon in continuity with remnant small intestine, and treating said patient with a GLP-2 receptor agonist using a dosing regimen effective to enhance intestinal absorption by said patient, wherein said GLP-2 receptor agonist is selected from the group consisting of a GLP-2 peptide, a GLP-2 analog, a derivatized GLP-2 peptide or a derivatized GLP-2 analog.
2. A method according to claim 1 , wherein said patient has at least 25% colon in continuity with remnant small intestine.
3. A method according to claim 2 , wherein said patient has at least 50% colon in continuity with remnant small intestine.
4. A method according to claim 3 , wherein said patient has at least 75% colon in continuity with remnant small intestine.
5. A method according to claim 1 , wherein said patient has colon sufficient to produce endogenous GLP-2 plasma levels of at least 5 pmol/L in the fed state.
6. A method according to claim 5 , wherein said patient has colon sufficient to produce endogenous GLP-2 plasma levels of at least 10 pmol/L in the fed state.
7. A method according to claim 1 , wherein said remnant small intestine has a length of at least 25 cm.
8. A method according to claim 7 , wherein said remnant small intestine has a length of at least 50 cm.
9. A method according to claim 1 , wherein said enhancement of intestinal absorption is a decrease in fecal wet weight.
10. A method according to claim 1 , wherein said enhancement of intestinal absorption is an increase in urine wet weight.
11. A method according to claim 1 , wherein said dosing regimen comprises daily administration of said GLP-2 receptor agonist.
12. A method according to claim 1 , wherein said dosing regimen comprises administration of said GLP-2 receptor agonist over a period of at least 21 days.
13. A method according to claim 1 , wherein said GLP-2 receptor agonist is a mammalian GLP-2.
14. A method according to claim 13 , wherein said GLP-2 receptor agonist is human GLP-2 .
15. A method according to claim 1 , wherein said GLP-2 receptor agonist is a GLP-2 analog.
16. A method according to claim 15 , wherein said GLP-2 receptor agonist is a human GLP-2 analog.
17. A method according to claim 15 , wherein said GLP-2 receptor agonist is [Gly2]hGLP-2.
18. A method according to claim 11 , wherein said GLP-2 receptor agonist is administered at a daily dose of from 5 to 500 ug/kg/day.